During the past decade, Kumamoto Shinto General Hospital conducted 15 clinical trials. In the 10-year time frame, 15 clinical trials started and 8 clinical trials were completed, i.e. on average, 53.3% percent of trials that started reached the finish line to date. In the past 5 years, 6 clinical trials started and 7 clinical trials were completed. i.e. 116.7% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Kumamoto Shinto General Hospital" #1 sponsor was "Eli Lilly and Company" with 6 trials, followed by "Hoffmann-La Roche" with 4 trials sponsored, "Gilead Sciences" with 3 trials sponsored, "Pfizer" with 2 trials sponsored and "Amgen" with 2 trials sponsored. Other sponsors include -3 different institutions and companies that sponsored additional 7 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Kumamoto Shinto General Hospital" #1 collaborator was "Alliance Foundation Trials (AFT)" with 1 trials as a collaborator, "Breast International Group" with 1 trials as a collaborator, "Chugai Pharmaceutical" with 1 trials as a collaborator, "Frontier Science & Technology Research Foundation, Inc." with 1 trials as a collaborator and "Institut Jules Bordet/Clinical Trials Support Unit (IJB/CTSU)" with 1 trials as a collaborator. Other collaborators include -4 different institutions and companies that were collaborators in the rest 6 trials.

According to Clinical.Site data, the most researched conditions in "Kumamoto Shinto General Hospital" are "Breast Cancer" (4 trials), "Breast Neoplasms" (4 trials), "Nonalcoholic Steatohepatitis" (3 trials), "Anemia" (1 trials) and "Hepatitis C Virus Infection" (1 trials). Many other conditions were trialed in "Kumamoto Shinto General Hospital" in a lesser frequency.

Most popular intervention types in "Kumamoto Shinto General Hospital" are "Drug" (18 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (7 trials), "Paclitaxel" (4 trials), "Abemaciclib" (3 trials), "Atezolizumab" (3 trials) and "Cyclophosphamide" (2 trials). Other intervention names were less common.

The vast majority of trials in "Kumamoto Shinto General Hospital" are 17 trials for "All" genders and 1 trials for "Female" genders.

Currently, there are NaN active trials in "Kumamoto Shinto General Hospital". undefined are not yet recruiting, 3 are recruiting, 7 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 6 completed trials in Kumamoto Shinto General Hospital, undefined suspended trials, and 2 terminated clinical trials to date.

Out of the total trials that were conducted in Kumamoto Shinto General Hospital, 1 "Phase 1" clinical trials were conducted, 5 "Phase 2" clinical trials and 12 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 0 trials that are defined as “Not Applicable".